|
1
|
Braun J and Sieper J: Ankylosing
spondylitis. Lancet. 369:1379–1390. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Biasi D, Carletto A, Caramaschi P, Pacor
ML, Maleknia T and Bambara LM: Efficacy of methotrexate in the
treatment of ankylosing spondylitis: a three-year open study. Clin
Rheumatol. 19:114–117. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Quaden DH, De Winter LM and Somers V:
Detection of novel diagnostic antibodies in ankylosing spondylitis:
An overview. Autoimmun Rev. 15:820–832. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stolwijk C, Essers I, van Tubergen A,
Boonen A, Bazelier MT, De Bruin ML and de Vries F: The epidemiology
of extra-articular manifestations in ankylosing spondylitis: A
population-based matched cohort study. Ann Rheum Dis. 74:1373–1378.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Davey-Ranasinghe N and Deodhar A:
Osteoporosis and vertebral fracture in ankylosing spondylitis. Curr
Opin Rheumatol. 25:509–516. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van der Weijden MA, Claushuis TA, Nazari
T, Lems WF, Dijkmans BA and van der Horst-Bruinsma IE: High
prevalence of low bone mineral density in patients within 10 years
of onset of ankylosing spondylitis: A systematic review. Clin
Rheumatol. 31:1529–1535. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Singh HJ, Nimarpreet K, Ashima, Das S,
Kumar A and Prakash S: Study of bone mineral density in patients
with ankylosing spondylitis. J Clin Diagn Res. 7:2832–2835.
2013.PubMed/NCBI
|
|
8
|
Smith JA: Update on ankylosing
spondylitis: Current concepts in pathogenesis. Curr Allergy Asthma
Rep. 15:4892015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Machado MA, Moura CS, Ferré F, Bernatsky
S, Rahme E and Acurcio Fde A: Treatment persistence in patients
with rheumatoid arthritis and ankylosing spondylitis. Rev Saude
Publica. 50:502016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Davis JC: Understanding the role of tumor
necrosis factor inhibiton in ankylosing spondylitis. Semin
Arthritis Rheum. 34:268–278. 2005. View Article : Google Scholar
|
|
11
|
Prince DS, McUuigan LE and McGirr EE:
Working life and physical activity in ankylosing spondylit is pre
and post antitumor necrosis factor-alpha therapy. Int J Rheum Dis.
17:165–172. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Maxwell LJ, Zochling J, Boonen A, Singh
JA, Veras MM, Tanjong Ghogomu E, Benkhalti Jandu M, Tugwell P and
Wells GA: TNF-alpha inhibitors for ankylosing spondylitis. Cochrane
Database Syst Rev. Apr 18–2015.(Epub ahead of print). doi:
10.1002/14651858.CD005468.pub2. View Article : Google Scholar
|
|
13
|
Poddubnyy DA, Song IH and Sieper J: The
safety of celecoxib in ankylosing spondylitis treatment. Expert
Opin Drug Saf. 7:401–409. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rauner M, Thiele S, Fert I, Araujo LM,
Layh-Schmitt G, Colbert RA, Hofbauer C, Bernhardt R, Bürki A,
Schwiedrzik J, et al: Loss of bone strength in HLA-B27 transgenic
rats is characterized by a high bone turnover and is mainly
osteoclast-driven. Bone. 75:183–191. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rostom S, Dougados M and Gossec L: New
tools for diagnosing spondyloarthropathy. Joint Bone Spine.
77:108–114. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gerdhem P, Ivaska KK, Alatalo SL, Halleen
JM, Hellman J, Isaksson A, Pettersson K, Väänänen HK, Akesson K and
Obrant KJ: Biochemical markers of bone metabolism and prediction of
fracture in elderly women. J Bone Miner Res. 19:386–393. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Garnero P and Delmas PD: Contribution of
bone mineral density and bone turnover markers to the estimation of
risk of osteoporotic fracture in postmenopausal women. J
Musculoskelet Neuronal Interact. 4:50–63. 2004.PubMed/NCBI
|
|
18
|
Garnero P, Ferreras M, Karsdal MA,
Nicamhlaoibh R, Risteli J, Borel O, Qvist P, Delmas PD, Foged NT
and Delaissé JM: The type I collagen fragments ICTP and CTX reveal
distinct enzymatlc pathways of bone collagen degradation. J Bone
Miner Res. 18:859–867. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
van der Linden S, Valkenburg HA and Cats
A: Evaluation of diagnostic criteria for ankylosing spondylitis. A
proposal for modification of the New York criteria. Arthritis
Rheum. 27:361–268. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Song J, Zhou L, Chen L and Wu X:
Comparison of ASDAS, RAPID3 and BASDAI in assessing disease
activity of patients with ankylosing spondylitis. Acad J Second Mil
Med Univ. 36:909–913. 2015. View Article : Google Scholar
|
|
21
|
Garrett S, Jenkinson T, Kennedy LG,
Whitelock H, Gaisford P and Calin A: A new approach to defining
disease status in AS: The Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI). J Rheumatol. 21:2286–2291. 1994.PubMed/NCBI
|
|
22
|
Neubauer S, Cifaldi M, Mittendorf T,
Ganguli A, Wolff M and Zeidler J: Biologic TNF inhibiting agents
for treatment of rheumatoid arthritis persistence and dosing
patterns in Germany. Health Econ Rev. 4:322014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fleischmann RM, Cohen SB, Moreland LW,
Schiff M, Mease PJ, Smith DB, Keenan G and Kremer JM; iRAMT Study
Group, : Methotrexate dosage reduction in patients with rheumatoid
arthritis beginning therapy with infliximab: the Infliximab
Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial. Curr Med
Res Opin. 21:1181–1190. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang J, Zhang YM and Zhang JL: Efficacy
of etanercept in patients with ankylosing spondylitis: A
double-blind, randomized, placebo controlled trial. Zhongguo Xin
Yao Za Zhi. 18:1846–1849, 1881. 2009.(In Chinese).
|
|
25
|
Chu B, Lu MQ, Wu MQ, Shi L, Fu LN, Gao S,
Fang LJ, Xiang QQ and Bao L: Clinical characteristics of bone
disease in multiple myeloma and clinical significance of monitoring
bone metabolic markers. Zhonghua Yi Xue Za Zhi. 96:1424–1429.
2016.(In Chinese). PubMed/NCBI
|
|
26
|
Fang Z, Li Y, Jiang Y and Yang F:
Significance of dynamic monitoring of bone metabolites in patients
with ankylosing spondylitis. Zhong Guo Yi Yuan Xie Hui. 4:447–449.
2014.(In Chinese).
|
|
27
|
Speden DJ, Calin AI, Ring FJ and Bhalla
AK: Bone mineral density, calcaneal ultrasound, and bone turnover
markers in women with ankylosing spondylitis. J Rheumatol.
29:516–521. 2002.PubMed/NCBI
|
|
28
|
Liu YF, Dong H, Tu SH, Zheng CH, Liu PL
and Hu YH: Etanercept in the treatment of ankylosing spondylitis: A
systematic review and meta-analysis. Exp Ther Med. 8:1585–1592.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Marakli SS, Uzun S, Ozbek S and Tuncer I:
Dermatitis herpetiformis in a patient receiving infliximab for
ankylosing spondylitis. Eur J Dermatol. 18:88–89. 2008.PubMed/NCBI
|
|
30
|
McLeod C, Bagust A, Boland A, Dagenais P,
Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R and Walley T:
Adalimumab, etanercept and infliximab for the treatment of
ankylosing spondylitis: a systematic review and economic
evaluation. Health Technol Assess. 11:1–158. 2007. View Article : Google Scholar
|
|
31
|
Korczowska I, Przepiera-Bedzak H, Brzosko
M, Lacki JK, Trefler J and Hrycaj P: Bone tissue metabolism in men
with ankylosing spondylitis. Adv Med Sci. 56:264–269. 2011.
View Article : Google Scholar : PubMed/NCBI
|
